(kroe FEL e mer)
Symptomatic relief of noninfectious diarrhea in patients with HIV/AIDS on antiretroviral therapy
There are no contraindications listed in the manufacturer 's labeling.
Diarrhea, noninfectious (associated with antiretroviral therapy for HIV/AIDS): Oral: 125 mg twice daily
No dosage adjustment provided in the manufacturer 's labeling.
No dosage adjustment provided in the manufacturer 's labeling.
May be administered orally with or without food. Swallow whole; do not crush or chew.
May be taken with or without food.
Store at 20 ‚ °C to 25 ‚ °C (68 ‚ °F to 77 ‚ °F); excursions permitted to 15 ‚ °C to 30 ‚ °C (59 ‚ °F to 86 ‚ °F).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet Delayed Release, Oral:
Fulyzaq: 125 mg [contains methylparaben, propylparaben]
There are no known significant interactions.
1% to 10%:
Central nervous system: Anxiety (2%), depression (1% to 2%), dizziness (1% to 2%)
Dermatologic: Acne vulgaris (1% to 2%), dermatitis (1% to 2%)
Gastrointestinal: Flatulence (3%), nausea (3%), abdominal distention (2%), giardiasis (2%), hemorrhoids (2%), abdominal pain (1% to 2%), constipation (1% to 2%), dyspepsia (1% to 2%), gastroenteritis (1% to 2%), xerostomia (1% to 2%)
Genitourinary: Urinary tract infection (2%), pollakiuria (1% to 2%)
Hematologic & oncologic: Leukopenia (1% to 2%)
Hepatic: Hyperbilirubinemia (1% to 3%), increased serum ALT (2%), increased serum AST (1% to 2%)
Hypersensitivity: Seasonal allergy (1% to 2%)
Infection: Herpes zoster (1% to 2%)
Neuromuscular & skeletal: Arthralgia (3%), back pain (3%), musculoskeletal pain (2%), limb pain (1% to 2%)
Renal: Nephrolithiasis (1% to 2%)
Respiratory: Upper respiratory tract infection (6%), bronchitis (4%), cough (4%), nasopharyngitis (2%), sinusitis (1% to 2%)
Disease-related concerns:
- HIV/AIDS: CD4 cell count and viral load do not have a clinical impact on crofelemer treatment; no adjustments are necessary based on CD4 cell count or viral load.
- Infectious diarrhea: Crofelemer is not indicated for infectious diarrhea; there is a risk of inadequate or delayed treatment if used when infectious diarrhea is present. Rule out infectious causes for diarrhea prior to initiating treatment.
C
Adverse events were observed in some animal reproduction studies; however, maternal toxicity was also present. Systemic absorption following oral administration is limited.
Inhibits cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion channel and calcium activated chloride ion channels at the enterocyte luminal membrane. This regulates fluid secretion and water loss (high volume) due to diarrhea, normalizing chloride ion and water flow in the GI tract.
Minimal systemic absorption
- Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
- Patient may experience flatulence, cough, pharyngitis, rhinitis, or rhinorrhea (HCAHPS).
- Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.